111 related articles for article (PubMed ID: 16263821)
1. Wnt/beta-catenin signaling mediates antineoplastic effects of imatinib mesylate (gleevec) in anaplastic thyroid cancer.
Rao AS; Kremenevskaja N; von Wasielewski R; Jakubcakova V; Kant S; Resch J; Brabant G
J Clin Endocrinol Metab; 2006 Jan; 91(1):159-68. PubMed ID: 16263821
[TBL] [Abstract][Full Text] [Related]
2. Lithium stimulates proliferation in cultured thyrocytes by activating Wnt/beta-catenin signalling.
Rao AS; Kremenevskaja N; Resch J; Brabant G
Eur J Endocrinol; 2005 Dec; 153(6):929-38. PubMed ID: 16322400
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of ABL tyrosine kinase potentiates radiation-induced terminal growth arrest in anaplastic thyroid cancer cells.
Podtcheko A; Ohtsuru A; Namba H; Saenko V; Starenki D; Palona I; Sedliarou I; Rogounovitch T; Yamashita S
Radiat Res; 2006 Jan; 165(1):35-42. PubMed ID: 16392960
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesylate (gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro.
Dziba JM; Ain KB
J Clin Endocrinol Metab; 2004 May; 89(5):2127-35. PubMed ID: 15126530
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of imatinib in patients with advanced anaplastic thyroid cancer.
Ha HT; Lee JS; Urba S; Koenig RJ; Sisson J; Giordano T; Worden FP
Thyroid; 2010 Sep; 20(9):975-80. PubMed ID: 20718683
[TBL] [Abstract][Full Text] [Related]
6. Imatinib enhances docetaxel-induced apoptosis through inhibition of nuclear factor-κB activation in anaplastic thyroid carcinoma cells.
Kim E; Matsuse M; Saenko V; Suzuki K; Ohtsuru A; Mitsutake N; Yamashita S
Thyroid; 2012 Jul; 22(7):717-24. PubMed ID: 22650230
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapeutic alteration of β-catenin and c-kit expression by imatinib in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
Schultz JD; Sommer JU; Hoedt S; Erben P; Hofheinz RD; Faber A; Thorn C; Hörmann K; Sauter A
Oncol Rep; 2012 Jan; 27(1):270-80. PubMed ID: 21993766
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms of action of imatinib mesylate in human ovarian cancer: a proteomic analysis.
Patel BB; He YA; Li XM; Frolov A; Vanderveer L; Slater C; Schilder RJ; von Mehren M; Godwin AK; Yeung AT
Cancer Genomics Proteomics; 2008; 5(3-4):137-49. PubMed ID: 18820368
[TBL] [Abstract][Full Text] [Related]
9. Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine models.
Gobin B; Moriceau G; Ory B; Charrier C; Brion R; Blanchard F; Redini F; Heymann D
PLoS One; 2014; 9(3):e90795. PubMed ID: 24599309
[TBL] [Abstract][Full Text] [Related]
10. Phosphatidylinositol-3 kinase inhibitors reproduce the selective antiproliferative effects of imatinib on chronic myeloid leukaemia progenitor cells.
Marley SB; Lewis JL; Schneider H; Rudd CE; Gordon MY
Br J Haematol; 2004 May; 125(4):500-11. PubMed ID: 15142121
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of anaplastic thyroid cancer cells.
Catalano MG; Fortunati N; Pugliese M; Marano F; Ortoleva L; Poli R; Asioli S; Bandino A; Palestini N; Grange C; Bussolati B; Boccuzzi G
J Clin Endocrinol Metab; 2012 Jul; 97(7):E1150-9. PubMed ID: 22563106
[TBL] [Abstract][Full Text] [Related]
12. Quercetin inhibit human SW480 colon cancer growth in association with inhibition of cyclin D1 and survivin expression through Wnt/beta-catenin signaling pathway.
Shan BE; Wang MX; Li RQ
Cancer Invest; 2009 Jul; 27(6):604-12. PubMed ID: 19440933
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinase inhibitor STI-571/Gleevec down-regulates the beta-catenin signaling activity.
Zhou L; An N; Haydon RC; Zhou Q; Cheng H; Peng Y; Jiang W; Luu HH; Vanichakarn P; Szatkowski JP; Park JY; Breyer B; He TC
Cancer Lett; 2003 Apr; 193(2):161-70. PubMed ID: 12706873
[TBL] [Abstract][Full Text] [Related]
14. Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fibrotic diseases.
Vittal R; Zhang H; Han MK; Moore BB; Horowitz JC; Thannickal VJ
J Pharmacol Exp Ther; 2007 Apr; 321(1):35-44. PubMed ID: 17218487
[TBL] [Abstract][Full Text] [Related]
15. The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells.
Podtcheko A; Ohtsuru A; Tsuda S; Namba H; Saenko V; Nakashima M; Mitsutake N; Kanda S; Kurebayashi J; Yamashita S
J Clin Endocrinol Metab; 2003 Apr; 88(4):1889-96. PubMed ID: 12679488
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma.
Frank-Raue K; Fabel M; Delorme S; Haberkorn U; Raue F
Eur J Endocrinol; 2007 Aug; 157(2):215-20. PubMed ID: 17656601
[TBL] [Abstract][Full Text] [Related]
17. Appropriate modulation of autophagy sensitizes malignant peripheral nerve sheath tumor cells to treatment with imatinib mesylate.
Okano M; Sakata N; Ueda S; Takemura T
J Pediatr Hematol Oncol; 2014 Apr; 36(3):200-11. PubMed ID: 24136016
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Zhang GS; Liu DS; Dai CW; Li RJ
Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
[TBL] [Abstract][Full Text] [Related]
19. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
[TBL] [Abstract][Full Text] [Related]
20. Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells.
Aiello A; Pandini G; Frasca F; Conte E; Murabito A; Sacco A; Genua M; Vigneri R; Belfiore A
Endocrinology; 2006 Sep; 147(9):4463-75. PubMed ID: 16777971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
